Skip to content

The biomarkers of acute respiratory distress syndrome

Role of MTDs in amplification of inflammatory response of ALI and systemic intervention study

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR-DDD-17013370
Enrollment
Unknown
Registered
2017-11-14
Start date
2017-09-01
Completion date
Unknown
Last updated
2017-11-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

acute respiratory distress syndrome

Interventions

Gold Standard:Clinical outcome, meet the Berlin Definition of ARDS
Index test:Damage&#32
molecular

Sponsors

West China Hospital,Sichuan University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 90 Years

Inclusion criteria

Inclusion criteria: For ARDS patients: 1) Aged at least 18 years old; 2) Those who meet the Berlin Definition of ARDS. For control subjects: 1) Aged at least 18 years old; 2) Those who were required to receive bronchofibroscope tests following their doctors advice; 3) Those who were not diagnosed with ARDS.;Inclusion criteria: For ARDS patients: 1) Aged at least 18 years old; 2) Those who meet the Berlin Definition of ARDS. For control subjects: 1) Aged at least 18 years old; 2) Those who were required to receive bronchofibroscope tests following their doctors advice; 3) Those who were not diagnosed with ARDS.

Exclusion criteria

Exclusion criteria: For ARDS patients: 1) Those who could not tolerate bronchofibroscope test and BALF collection; For control subjects: 1) Those who were diagnosed with COPD, asthma or other chronic airway inflammatory diseases; 2) Those who were diagnosed with pulmonary tuberculosis; 3) Subjects with pulmonary lobotomy history.;Exclusion criteria: For ARDS patients: 1) Those who could not tolerate bronchofibroscope test and BALF collection; For control subjects: 1) Those who were diagnosed with COPD, asthma or other chronic airway inflammatory diseases; 2) Those who were diagnosed with pulmonary tuberculosis; 3) Subjects with pulmonary lobotomy history.

Design outcomes

Primary

MeasureTime frame
proteomics;Damage associated molecular;;proteomics;Damage associated molecular;

Countries

China

Contacts

Public ContactFuqiang Wen;Fuqiang Wen ;

West China Hospital, Sichuan University;West China Hospital, Sichuan University

wenfuqiang.scu@gmail.com;wenfuqiang.scu@gmail.com+86 18980601258;+86 18980601258

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 12, 2026